1. United States Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
VitaNova Life Sciences Corporation

VitaNova Life Sciences Corporation

OOTC:VNOV
4.25
USD
-0.30
(-6.59%)
-0.01EPS
19.84MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.06
0.02
0.16
0.32
0.36
0.39
Basic EPS, GAAP
- -
- -
-0.05
-0.04
-0.03
0.07
-0.01
0.04
0.1
- -
-0.01
Free Cash Flow per Basic Share
- -
-0.02
-0.03
-0.03
-0.02
- -
-0.01
-0.11
0.02
0.1
0.07
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
0.02
-0.03
-0.06
-0.09
-0.02
-0.03
0.13
0.23
0.25
0.23
Tangible Book Value per Share
- -
0.02
-0.03
-0.06
-0.09
-0.02
-0.03
0.13
0.23
0.25
0.23
Basic Weighted Avg Shares
3
2
2
2
2
2
2
4
8
8
8
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
1
3
3
3
Operating Margin (%)
- -
- -
- -
- -
- -
-11.14
-63.76
36.03
45.39
0.12
-2.66
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
31.53
29.36
666.84
- -
Profit Margin (%)
- -
- -
- -
- -
- -
116.4
-63.76
24.68
31.96
-1.23
-3.52
Working Capital
- -
- -
- -
- -
- -
- -
- -
1
2
2
2
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
1
2
2
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
26.52
51.48
-0.95
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-133.25
- -
28.27
57.61
-1.88
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
57.39
-1.88
-6.02

Capital Structure

USD

•

in mil. unless spec.
Jan'26
Apr'26
Jul'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
- -
12
20

Working Capital

USD

•

in mil. unless spec.
Jan'26
Apr'26
Jul'27
Total Current Assets
2
2
2
Cash, Cash Equivalents & STI
1
2
2
Accounts Receivable, Net
1
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-361.15%
7.44%
Free Cash Flow
- -
290.94%
322.47%
Net Income, GAAP
- -
-153.47%
-104.38%
Sales/Revenue/Turnover
- -
- -
13.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
2
3
2026
- -
- -
1
2
3
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.01
- -
0.01
0.1
0.1
2026
-0.01
- -
-0.01
- -
- -
2027
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Qiu Ping Lu
Full Time Employees
7
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
New York United States
CIK
0001699709
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
VitaNova Life Sciences Corporation is a biotechnology and life sciences company focused on the research, development, manufacturing, and commercialization of regenerative therapeutics, cellular health solutions, and advanced longevity products. The company operates across the biopharmaceutical, nutraceutical, and clinical research sectors, offering a diversified portfolio of products and services that includes cellular rejuvenation therapies; peptide-based bioactive compounds; clinical-grade longevity and anti-aging dietary supplements; regenerative biomaterials; specialized nutritional formulations; in vitro diagnostic screening kits; preclinical contract research and development services; and intellectual property licensing for proprietary drug candidates. VitaNova Life Sciences Corporation serves healthcare practitioners, clinical research organizations, biopharmaceutical companies, and retail consumers across North America and select international markets. The company was founded in 2018 and is headquartered in the United States. In recent developments, VitaNova Life Sciences Corporation completed a comprehensive corporate reorganization and rebranding to refocus its core strategy on longevity biotechnology and cellular regenerative medicine. The company expanded its development pipeline through new strategic licensing partnerships and research alliances with biomedical institutions, launched its next-generation line of cellular health formulations, and secured private placement financing to fund ongoing preclinical research and regulatory submission pathways. Furthermore, VitaNova broadened its commercial reach by establishing new wholesale and direct-to-consumer distribution agreements across expanding global wellness and clinical markets.